C-EARLY results support Cimzia's use sooner for severe RA
This article was originally published in Scrip
Data presented at the European League Against Rheumatism (EULAR) annual congress in Rome support the early use of UCB's anti-TNF drug Cimzia (certolizumab pegol) in certain rheumatoid arthritis patients who have not yet been treated with methotrexate or other disease-modifying anti-rheumatic drugs (DMARDs).
You may also be interested in...
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.
Merck & Co is gradually catching up with Roche in PD-1/L1 first-line triple-negative breast cancer treatment, but its presentation at ASCO on Keynote-355 includes mixed PFS results. Overall survival data will be key to Keytruda’s competitiveness.
INFOGRAPHIC: A snapshot of the compensation packages granted to the chiefs of the world’s biggest pharma companies, along with key performance stats for the businesses they lead.